Elevance Health, INC Form 4 insider transactions

Director Ramiro G Peru acquired 601 shares of Elevance Health common stock on May 14, 2025, through deferred stock units accrued under the company's Board of Directors Compensation Program.

Director Antonio F. Neri acquired 601 deferred stock units of Elevance Health, Inc. under the company's Board of Directors Compensation Program.

Director Bahija Jallal reports acquisition of deferred stock units in Elevance Health, Inc.

Director Hay Lewis III acquired 601 deferred stock units in Elevance Health, Inc. on May 14, 2025.

Director Robert L. Dixon Jr. reports acquiring 601 deferred stock units of Elevance Health, Inc.

Director Kerry Clark acquired 601 deferred stock units in Elevance Health, Inc. on May 14, 2025, according to a Form 4 filing.

Elevance Health's EVP & CFO, Mark Kaye, sold 4,588 shares of common stock at $424.82 per share on April 24, 2025.

Ronald W. Penczek, CAO & Controller of Elevance Health, Inc., reported the sale of 443 shares of common stock at a price of $415.13 on March 10, 2025.

Elevance Health's EVP & President, Commercial, Kendrick Charles Morgan JR., reports acquisition and disposal of company stock and derivative securities.

Ronald W. Penczek, CAO & Controller of Elevance Health, reports acquisition and disposal of company stock and stock options.

Elevance Health's EVP, Chief Digital & Info Officer Ratnakar Lavu reports the acquisition and disposal of company stock and stock options.

Felicia Norwood, EVP & President of Government Health Benefits at Elevance Health, reports the acquisition and disposal of company stock and stock options.

Elevance Health's EVP & President Carelon & CarelonRx, Peter D Haytaian, reports acquisition and disposal of company stock and derivative securities.

Elevance Health's EVP & CFO, Mark Kaye, reports the acquisition and disposal of company stock and stock options.

Elevance Health's CEO, Gail Boudreaux, reports acquisition and disposal of company stock and derivative securities.

Elevance Health's EVP, CLO & CAO, Blair Williams Todt, reports stock withholding for tax liabilities and corrects a previous filing error related to restricted stock vesting.

Elevance Health's EVP & President, Commercial, Charles Morgan Kendrick JR, reports the acquisition and disposal of company stock on November 1, 2024.

Peter D. Haytaian, an EVP at Elevance Health, reports the acquisition and disposal of company stock related to vesting restricted stock units.

Elevance Health's EVP & President, Commercial, Charles Morgan Kendrick Jr., sold 7,417 shares of common stock at an average price of $432.14 on October 18, 2024.

Mark Kaye, EVP & CFO of Elevance Health, reports the disposition of 2,818 shares of common stock to cover tax liabilities related to vesting restricted stock.

Director Ramiro G Peru sold 753 shares of Elevance Health, Inc. (ELV) at a price of $531.52 on August 5, 2024, according to a Form 4 filing.

Elevance Health's CEO, Gail Boudreaux, executed multiple sales of common stock on July 22, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Director Robert L. Dixon Jr. sold 305 shares of Elevance Health, Inc. on July 19, 2024, at a price of $506.76 per share.

Director Elizabeth E. Tallett reports acquisition of deferred stock units in Elevance Health, Inc.

Deanna Strable-Soethout, a director of Elevance Health, Inc., reported the acquisition of deferred stock units under the company's Board of Directors Compensation Program.

Director Ryan M. Schneider reported acquiring 388 deferred stock units of Elevance Health, Inc.

Director Ramiro G Peru reports the acquisition of 388 deferred stock units in Elevance Health, Inc.

Director Antonio Neri reported the acquisition of deferred stock units in Elevance Health, Inc.

Director Bahija Jallal reported the acquisition of 388 deferred stock units of Elevance Health, Inc.

Director Lewis Hay III acquired 388 deferred stock units of Elevance Health, Inc. on May 15, 2024, under the company's Board of Directors Compensation Program.